GLPwatch
Endocrine and metabolic effects of Glucagon like peptide 1 receptor agonists (GLP1RA).
J Pak Med Assoc · 2016
Last updated 2026-05-28Glucagon-like peptide 1 receptor agonists (GLP1RAs) are being studied for effects beyond blood sugar control, including conditions like hypothalamic obesity, non-alcoholic steatohepatitis (NASH), and polycystic ovary syndrome (PCOS). The review explores how these drugs might be used across different areas of endocrinology and metabolism, while also addressing concerns related to their endocrine effects.
AI summary of the abstract below.
| Journal | J Pak Med Assoc, 2016 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.08 |
| NIH percentile | 6 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction, Chronic Kidney Disease, Mash, Heart Failure |
Abstract
This brief review describes the potential non-glycaemic effects and benefits of glucagon like peptide 1 receptor agonists (GLP1RA). It lists various indications in which this class of drugs has been used, and explains the rationale behind this use. The potential uses of GLP1RA extend across the entire spectrum of endocrinology and metabolism, from hypothalamic obesity to non-alcoholic steatohepatitis (NASH) to polycystic ovary syndrome (PCOS). The article also discusses and addresses endocrine-related concerns related to the GLP1RAs.
Verbatim abstract via PubMed 26968296 ↗